STANDARD INFUSION 1

  • Administer only as an intravenous (IV) infusion
  • Do not administer as an intravenous push or bolus
  • Premedicate patients with an antihistamine and acetaminophen prior to dosing
  • Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate
  • Depending on the severity of the infusion reaction and the required interventions, temporarily or permanently discontinue RITUXAN
    •  Resume infusion at a minimum 50% reduction in rate after symptoms have resolved
  • Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion reactions as needed
  • Closely monitor the following patients: those with preexisting cardiac or pulmonary conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (≥25,000/mm3)
  • See BOXED WARNING, DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS sections of the full Prescribing Information

ADMINISTRATION 1

SELECT IMPORTANT SAFETY INFORMATION

Infusion Reactions
  • RITUXAN can cause severe, including fatal, infusion-related reactions. Severe reactions typically occurred during the first infusion, with time to onset of 30 to 120 minutes
  • RITUXAN-induced infusion-related reactions and sequelae include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, anaphylactoid events, or death
  • Premedicate patients with an antihistamine and acetaminophen prior to dosing. Institute medical management (eg, glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. Depending on the severity of the infusion reaction and the required interventions, slow the infusion rate, interrupt the infusion, or permanently discontinue RITUXAN. Resume infusion at a minimum 50% reduction in rate after symptoms have resolved
  • Closely monitor the following patients: those with pre-existing cardiac or pulmonary conditions, those who experienced prior cardiopulmonary adverse reactions, and those with high numbers of circulating malignant cells (≥25,000/mm3)

NEXT: RATE 90-Minute Infusion >

Speech bubble icon

CONTACT YOUR REPRESENTATIVE

Interested in more information about RITUXAN clinical data?